Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 14, Issue 2, Pages -Publisher
CUREUS INC
DOI: 10.7759/cureus.21840
Keywords
psychopharmacology; fmr1; clinical management; behavioral problems; behavioral treatment; fragile x syndrome
Categories
Ask authors/readers for more resources
This narrative review collates recent evidence on the various management options of behavioral problems in fragile X syndrome (FXS), including pharmacological and non-pharmacological treatments, and provides a review of the newer avenues in FXS treatment.
Fragile X syndrome (FXS) is noted to be the leading cause of inherited intellectual disabilities and is caused by expansive cytosine-guanine-guanine (CGG) trinucleotide repeats in the fragile X mental retardation 1 gene (FMR1). FXS can display a wide range of behavioral problems in addition to intellectual and developmental issues. Management of these problems includes both pharmacological and non-pharmacological options and research on these different management styles has been extensive in recent years. This narrative review aimed to collate recent evidence on the various management options of behavioral problems in FXS, including the pharmacological and non-pharmacological treatments, and also to provide a review of the newer avenues in the FXS treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available